Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 3
2019 3
2020 4
2021 5
2022 2
2023 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients.
Malard F, Vekhoff A, Lapusan S, Isnard F, D'incan-Corda E, Rey J, Saillard C, Thomas X, Ducastelle-Lepretre S, Paubelle E, Larcher MV, Rocher C, Recher C, Tavitian S, Bertoli S, Michallet AS, Gilis L, Peterlin P, Chevallier P, Nguyen S, Plantamura E, Boucinha L, Gasc C, Michallet M, Dore J, Legrand O, Mohty M. Malard F, et al. Among authors: larcher mv. Nat Commun. 2021 May 25;12(1):3084. doi: 10.1038/s41467-021-23376-6. Nat Commun. 2021. PMID: 34035290 Free PMC article. Clinical Trial.
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia.
Fodil S, Raffoux E, Dumas PY, Desbrosses Y, Larosa F, Chantepie S, Larcher MV, Mear JB, Peterlin P, Hunault-Berger M, Hospital MA, Morel V, Lucas N, Vidal V, Salanoubat C, Michel J, Mediavilla C, Ojeda-Uribe M, Alexis M, Frayfer J, Carré M, Maillard N, Redjoul R, Banos A, Detrait M, Cluzeau T, Wickenhauser S, Chaoui D, Elassy M, Pigneux A, Dombret H, Récher C, Bertoli S; French AML Intergroup ALFA/FILO. Fodil S, et al. Among authors: larcher mv. Leuk Lymphoma. 2021 Jul;62(7):1756-1760. doi: 10.1080/10428194.2021.1881505. Epub 2021 Feb 17. Leuk Lymphoma. 2021. PMID: 33596765 No abstract available.
Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a 'Real-Life' Study.
Laurino M, Loron S, Larcher MV, Fossard G, Elhamri M, Deloire A, Balsat M, Barraco F, Labussière H, Ducastelle S, Renault M, Wattel E, Heiblig M, Salles G, Thomas X. Laurino M, et al. Among authors: larcher mv. Mediterr J Hematol Infect Dis. 2020 May 1;12(1):e2020020. doi: 10.4084/MJHID.2020.020. eCollection 2020. Mediterr J Hematol Infect Dis. 2020. PMID: 32395209 Free PMC article.
Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.
Daull AM, Dubois V, Labussière-Wallet H, Venet F, Barraco F, Ducastelle-Lepretre S, Larcher MV, Balsat M, Gilis L, Fossard G, Ghesquières H, Heiblig M, Ader F, Alcazer V. Daull AM, et al. Among authors: larcher mv. Front Immunol. 2022 Mar 4;13:841470. doi: 10.3389/fimmu.2022.841470. eCollection 2022. Front Immunol. 2022. PMID: 35309346 Free PMC article.
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Meur GL, Plesa A, Larcher MV, Fossard G, Barraco F, Loron S, Balsat M, Ducastelle-Leprêtre S, Gilis L, Thomas X, Ghesquières H, Tigaud I, Hayette S, Huet S, Sujobert P, Renault M, Thérèse RM, Michallet M, Labussière-Wallet H, Heiblig M. Meur GL, et al. Among authors: larcher mv. Transplant Cell Ther. 2023 Jan;29(1):38.e1-38.e9. doi: 10.1016/j.jtct.2022.09.003. Epub 2022 Sep 13. Transplant Cell Ther. 2023. PMID: 36108977 Free article.
Immunosuppression medication adherence after allogeneic hematopoietic stem cell transplant: Impact of a specialized clinical pharmacy program.
Charra F, Philippe M, Herledan C, Caffin AG, Larbre V, Baudouin A, Schwiertz V, Vantard N, Labussiere-Wallet H, Ducastelle-Leprêtre S, Barraco F, Balsat M, Larcher MV, Salles G, Rioufol C, Ranchon F. Charra F, et al. Among authors: larcher mv. J Oncol Pharm Pract. 2021 Mar 8:10781552211000115. doi: 10.1177/10781552211000115. Online ahead of print. J Oncol Pharm Pract. 2021. PMID: 33683151
Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
Plesa A, Roumier C, Gutrin J, Larcher MV, Balsat M, Cadassou O, Barraco F, Fossard G, Baudouin A, Labussière H, Tigaud I, Ducastelle S, Hayette S, Sujobert P, Heiblig M, Elhamri M, Thomas X. Plesa A, et al. Among authors: larcher mv. Leuk Res. 2021 Dec;111:106673. doi: 10.1016/j.leukres.2021.106673. Epub 2021 Jul 26. Leuk Res. 2021. PMID: 34364023 No abstract available.
19 results